Inactive

***AMENDMENT 0003*** THE PURPOSE OF THIS AMENDMENT IS TO REMOVE DFARS CLAUSE 252.204-7012 FROM THE SOLICITATION. THE QUOTE DUE DATE IS HEREBY EXTENDED TO 12 SEP 2025 AT 1600 CST. ***AMENDMENT 0002*** ... ***AMENDMENT 0003*** THE PURPOSE OF THIS AMENDMENT IS TO REMOVE DFARS CLAUSE 252.204-7012 FROM THE SOLICITATION. THE QUOTE DUE DATE IS HEREBY EXTENDED TO 12 SEP 2025 AT 1600 CST. ***AMENDMENT 0002*** THE PURPOSE OF THIS AMENDMENT IS TO REVISE THE REQUIREMENT FROM A FIVE-YEAR ORDERING PERIOD TO A ONE-YEAR ORDERING PERIOD. THE QUOTE DUE DATE IS HEREBY EXTENDED TO 11 SEP 2025 AT 1600 CST. ***AMENDMENT 0001*** THE PURPOSE OF THIS AMENDMENT IS TO: (1) INCORPORATE CLIN 0011 "POST AWARD CONFERENCE" WHICH WILL SATISFY THE $100.00 MINIMUM GUARANTEE ESTABLISHED FOR THE RESULTANT IDIQ CONTRACT AND (2) UPDATE THE STATEMENT OF WORK TO SPECIFY THE DELIVERY TIMEFRAME FOR IOFLUPANE. Solicitation W81K00-25-Q-A125 is hereby issued for various radiopharmaceuticals in support of Brooke Army Medical Center (BAMC), JBSA Fort Sam Houston, TX. The resultant contract will be a Firm-Fixed-Price (FFP) Indefinite Delivery Indefinite Quantity (IDIQ) contract with a five-year ordering period. Period of Performance: 01 OCT 2025 through 30 SEP 2030. Refer to attached Solicitation W81K00-25-Q-A125 and Statement of Work. Solicitation PSC/NAICS 6505 (Drugs and Pharmaceutical Products) / 325412 (Phrmaceutical Preparation Manufacturing)